GS
FOLD

GTS Securities’s Amicus Therapeutics FOLD Stock Holding History

GTS Securities’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,100
Closed -$243K – 4048
2023
Q4 		$243K Sell
17,100
-26,600
-61% -$302K ﹤0.01% 3399
2023
Q3 		$531K Buy
+43,700
New +$564K ﹤0.01% 2560

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GTS Securities's FOLD Position: Q4 2024 in Review

GTS Securities sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 13,166 shares — an estimated $141K sold.

GTS Securities first reported a position in FOLD in Q2 2023 and held it in 4 quarters. The position peaked at $534K in Q3 2023. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • GTS Securities reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 13,166 Amicus Therapeutics shares in Q4 2024, an estimated $141K.
  • GTS Securities first reported a position in Amicus Therapeutics in Q2 2023 and held it in 4 quarters.
  • GTS Securities's Amicus Therapeutics position peaked at $534K in Q3 2023.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.